On August 24, 2023 Xiling Lab reported Notice on Approval for Drug Clinical Trial was issued by the National Medical Products Administration (NMPA) for SMP-656, the first ADC developed by Xiling Lab.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SMP-656 is a HER2-targeting eribulin ADC based on our innovative XL-XDC platform. The selection of eribulin as the toxin, which is characterized by its novel mechanism and exceptionally high synthesis technology barriers, offers inherent differentiated advantages. The introduction of a proprietary SuperHydro linker, which effectively block retro-Michael de-conjugation, significantly improves conjugate stability during circulation and enhance payload delivery to the target, in turn, allowing higher dosing and better tumor penetration.
We envision that SMP-656 holds a great potential to be a best-in-class HER2-targeting ADC, by overcoming primary resistance for approved ADCs or secondary resistance for cytotoxic agents.
(Press release, Xiling Lab, AUG 24, 2023, View Source [SID1234669422])